AstraZeneca, a leading British pharmaceutical company, has entered into two significant agreements with Alteogen<\/a>, amounting to a potential total of $1.35 billion, aimed at developing subcutaneous formulations of various oncology products. This partnership comes into play amid a complex patent dispute involving Halozyme<\/a>, the developer of rival hyaluronidase enzymes, which poses potential risks to AstraZeneca\u2019s advancement of these cancer drugs.<\/p>\n In a recent announcement on Monday, AstraZeneca declared that it has acquired exclusive rights to utilize Alteogen\u2019s hyaluronidase protein, ALT-B4, for the creation and commercialization of subcutaneous versions of \u201cseveral oncology assets.\u201d The deals, as disclosed in Alteogen’s filings with the Korea Exchange, comprise two separate agreements. The first agreement entails an upfront payment of $25 million accompanied by potential milestone payments reaching up to $725 million. The second deal includes an upfront payment of $20 million, with potential milestones totaling $580 million. However, AstraZeneca has chosen to withhold information regarding the specific oncology assets involved and the finer financial details.<\/p>\n The move to collaborate with Alteogen occurs despite a burgeoning patent dispute concerning ALT-B4. Halozyme has indicated it may take legal action against Merck & Co. over its subcutaneous formulation of Keytruda, a prominent cancer drug that leverages Alteogen\u2019s technology. Halozyme contends that the use of ALT-B4 in commercial applications would infringe upon its modified hyaluronidase (Mdase) patent portfolio. Merck is aiming for an upcoming product launch of the new Keytruda formulation in the United States, pending approval from the FDA<\/a>.<\/p>\n Halozyme has reportedly reached out to Merck to negotiate a potential licensing agreement but has signaled readiness to initiate legal action to prevent the sale of subcutaneous Keytruda if necessary. In response to inquiries about a similar patent dispute affecting AstraZeneca’s collaboration with Alteogen, a spokesperson for AstraZeneca refrained from commenting on third-party patent matters, expressing enthusiasm for the partnership with Alteogen.<\/p>\nDetails of the Agreements<\/h2>\n
Patent Disputes and Risks<\/h2>\n
Other Collaborations and Market Context<\/h2>\n